CLOV
BEARISH
$1.9
Live
Clover Health Investments, Corp. · NASDAQ
Target $2.82
(+48.2%)
$1.58
52W Range
$3.92
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 08, 2026
Market cap
$996.87M
P/E
N/A
ROE
-26.3%
Profit margin
-4.4%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
75%
CLOV shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Concerns include weak profitability or high valuation.
Key Strengths
Strong revenue growth of 44.7%
Key Risks
Low profit margin of -4.4%
Weak financial trend (Piotroski F-Score: 1/9)
Weak ROE of -26.3%
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
35
Weak
50
65
30
30
0
AI Verdict
CLOV shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Concerns include weak profitability or high valuation.
Key drivers: Strong revenue growth of 44.7%, Low profit margin of -4.4%, Weak financial trend (Piotroski F-Score: 1/9)
Confidence
35%
Value
50/100
Rule-based valuation (P/E + Graham).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Future
65/100
Rule-based growth outlook.
Positives
- Revenue growth running at 44.7%.
Watchpoints
No urgent risks highlighted.
Past
30/100
Historical performance + price trend: Shares moved -78.5% over 5Y and -40.8% over 1Y.
Positives
- Insufficient data for clear positives.
Watchpoints
- ROE only -26.3%.
- Thin profit margins.
Health
30/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Dividend
0/100
Dividend policy fallback.
Positives
- Insufficient data for clear positives.
Watchpoints
- No regular dividend payments.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$1.9
Analyst Target
$2.82
Upside/Downside
+48.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for CLOV and closest competitors.
Updated 2026-04-07
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
CLOV
Clover Health Investments, Corp.
Primary
|
-78.5% | +126.7% | -40.8% | -29.6% | -5.0% | +8.0% |
|
ASTH
Astrana Health, Inc.
Peer
|
-19.7% | -41.8% | -41.4% | -36.4% | -7.6% | +2.4% |
|
AKTS
Aktis Oncology, Inc.
Peer
|
-15.2% | -15.2% | -15.2% | -15.2% | +5.2% | +1.0% |
|
ABCL
AbCellera Biologics Inc.
Peer
|
-90.7% | -53.9% | +45.4% | -21.9% | +11.5% | +1.2% |
|
ABUS
Arbutus Biopharma Corporation
Peer
|
+34.8% | +48.0% | +34.4% | +0.9% | +3.2% | +6.6% |
CLO
Clover Health Investments, Corp.
Primary
5Y
-78.5%
3Y
+126.7%
1Y
-40.8%
6M
-29.6%
1M
-5.0%
1W
+8.0%
AST
Astrana Health, Inc.
Peer
5Y
-19.7%
3Y
-41.8%
1Y
-41.4%
6M
-36.4%
1M
-7.6%
1W
+2.4%
AKT
Aktis Oncology, Inc.
Peer
5Y
-15.2%
3Y
-15.2%
1Y
-15.2%
6M
-15.2%
1M
+5.2%
1W
+1.0%
ABC
AbCellera Biologics Inc.
Peer
5Y
-90.7%
3Y
-53.9%
1Y
+45.4%
6M
-21.9%
1M
+11.5%
1W
+1.2%
ABU
Arbutus Biopharma Corporation
Peer
5Y
+34.8%
3Y
+48.0%
1Y
+34.4%
6M
+0.9%
1M
+3.2%
1W
+6.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
21.11
PEG Ratio
N/A
P/B Ratio
3.19
P/S Ratio
0.52
EV/Revenue
0.45
EV/EBITDA
-10.09
Market Cap
$996.87M
Profitability
Profit margins and return metrics
Profit Margin
-4.45%
Operating Margin
-10.11%
Gross Margin
18.46%
ROE
-26.33%
ROA
-9.53%
Growth
Revenue and earnings growth rates
Revenue Growth
+44.7%
Earnings Growth
N/A
Q/Q Revenue Growth
+44.74%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
1.47
Good
Quick Ratio
1.34
Good
Cash/Share
$0.23
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.5B
Gross Margin
15.2%
Op. Margin
-10.1%
Net Margin
-10.1%
Total Assets
$0.5B
Liabilities
$0.2B
Equity
$0.3B
Debt/Equity
0.75x
Operating CF
$-0.1B
CapEx
$-0.0B
Free Cash Flow
$-0.1B
FCF Yield
101%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-05
$N/A
2026-02-25
$-0.1
+2.1% surprise
2025-11-04
$N/A
-83.5% surprise
2025-08-05
$-0.02
+25.2% surprise
Healthcare Sector Comparison
Comparing CLOV against 162 companies in the Healthcare sector
(15 bullish, 52 neutral, 95 bearish)
Return on Equity (ROE)
-26.33%
This Stock
vs
-42.35%
Sector Avg
-37.8%
(Below Avg)
Profit Margin
-4.45%
This Stock
vs
-18.25%
Sector Avg
-75.6%
(Weaker)
Revenue Growth
44.7%
This Stock
vs
114.26%
Sector Avg
-60.9%
(Slower)
Current Ratio
1.47
This Stock
vs
3.36
Sector Avg
-56.1%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
CLOV
Clover Health Investments, Corp.
|
BEARISH | $996.87M | - | -26.3% | -4.4% | $1.9 | |
|
ASTH
Astrana Health, Inc.
|
BEARISH | $1.02B | 107.0 | 1.8% | 0.3% | $20.33 | Compare |
|
AKTS
Aktis Oncology, Inc.
|
BEARISH | $1.05B | - | -26.5% | -% | $18.99 | Compare |
|
ABCL
AbCellera Biologics Inc.
|
NEUTRAL | $1.06B | - | -14.5% | -194.9% | $3.49 | Compare |
|
ABUS
Arbutus Biopharma Corporation
|
BEARISH | $872.03M | - | -38.5% | -237.9% | $4.53 | Compare |
CLOV
Clover Health...
BEARISH
Mkt Cap
$997M
P/E
-
ROE
-26.3%
Price
$1.9
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | REYNOSO JAMIE L. | Officer | Stock Award | 159,384 | - |
| 2026-04-01 | TOY ANDREW | Chief Executive Officer | Stock Award | 956,307 | - |
| 2026-04-01 | PRIEST BRADY PATRICK | Officer | Stock Award | 191,261 | - |
| 2026-04-01 | WAI CONRAD | Officer | Stock Award | 267,766 | - |
| 2026-04-01 | SOARES KAREN | Officer | Stock Award | 382,522 | - |
| 2026-03-18 | REYNOSO JAMIE L. | Officer | Sale | 5,833 | $11,141 |
| 2026-03-04 | PRIEST BRADY PATRICK | Officer | Sale | 175,000 | $379,750 |
| 2026-01-20 | REYNOSO JAMIE L. | Officer | Sale | 4,597 | $11,860 |
| 2026-01-07 | REYNOSO JAMIE L. | Officer | Sale | 2,102 | $5,318 |
| 2026-01-07 | GARIPALLI VIVEK | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award | 1,655,949 | - |
| 2026-01-06 | TRAN THOMAS L | Director | Stock Award | 79,365 | - |
| 2026-01-06 | ROBINSON WILLIAM G JR | Director | Stock Award | 79,365 | - |
| 2026-01-06 | KOUZOUKAS DEMETRIOS L | Director | Stock Award | 79,365 | - |
| 2026-01-06 | EDWARDS CARLADENISE ARMBRISTER | Director | Stock Award | 79,365 | - |
| 2026-01-06 | LOENGARD ANNA U | Director | Stock Award | 79,365 | - |
REYNOSO JAMIE L.
Officer
2026-04-01
159,384 shares
TOY ANDREW
Chief Executive Officer
2026-04-01
956,307 shares
PRIEST BRADY PATRICK
Officer
2026-04-01
191,261 shares
WAI CONRAD
Officer
2026-04-01
267,766 shares
SOARES KAREN
Officer
2026-04-01
382,522 shares
REYNOSO JAMIE L.
Officer
2026-03-18
5,833 shares
·
$11,141
PRIEST BRADY PATRICK
Officer
2026-03-04
175,000 shares
·
$379,750
REYNOSO JAMIE L.
Officer
2026-01-20
4,597 shares
·
$11,860
REYNOSO JAMIE L.
Officer
2026-01-07
2,102 shares
·
$5,318
GARIPALLI VIVEK
Director and Beneficial Owner of more than 10% of a Class of Security
2026-01-07
1,655,949 shares
TRAN THOMAS L
Director
2026-01-06
79,365 shares
ROBINSON WILLIAM G JR
Director
2026-01-06
79,365 shares
KOUZOUKAS DEMETRIOS L
Director
2026-01-06
79,365 shares
EDWARDS CARLADENISE ARMBRISTER
Director
2026-01-06
79,365 shares
LOENGARD ANNA U
Director
2026-01-06
79,365 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
3 analysts
Canaccord Genuity
2026-03-20
Buy
Buy
Leerink Partners
2026-03-05
Market Perform
Market Perform
Canaccord Genuity
2026-01-20
Buy
Buy
Canaccord Genuity
2025-11-06
Buy
Buy
Past News Coverage
Recent headlines mentioning CLOV from our newsroom.
Newest → oldest
No matching news yet.